AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
- Conditions
- Anxiety Disorders
- First Posted Date
- 2006-04-13
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 575
- Registration Number
- NCT00314210
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
🇺🇸Research SIte, Middleburg Heights, Ohio, United States
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00313183
- Locations
- 🇺🇸
Research Site, New York, New York, United States
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
- Conditions
- Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT00313170
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00313794
- Locations
- 🇨🇦
Research Site, Quebec, Canada
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
- Conditions
- Diabetes
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 768
- Registration Number
- NCT00313313
- Locations
- 🇺🇸
Stewart Medical Group, Alhambra, California, United States
🇺🇸Valley Research, Fresno, California, United States
🇺🇸Randall Shue, D.O., Los Angeles, California, United States
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 933
- Registration Number
- NCT00313209
- Locations
- 🇿🇦
Altana Pharma/Nycomed Investigational Sites, Kapstadt, South Africa
🇬🇧Altana Pharma/Nycomed Investigational Site, Watford, United Kingdom
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- Drug: best supportive care
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00312975
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: exenatide, long acting release
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 303
- Registration Number
- NCT00308139
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
🇺🇸Research Site 023, Butte, Montana, United States
🇺🇸Research Site 518, San Diego, California, United States
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00306891
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00306540
- Locations
- 🇦🇺
Research Site, Melbourne, Victoria, Australia